AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) have presented Phase I/II clinical data for their T-cell engager, Tepkinly/Epkinly (epcoritamab), in patients with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of therapy. Interim results, with a median follow-up of 17.4 months, showed that the CD3xCD20 bispecific antibody (BsAb) achieved an overall response rate (ORR) of 82%, meeting the primary endpoint, and a complete response (CR) rate of 63%. The median duration of response or duration of CR has not been reached, and no new safety signals were identified.
Significantly, the ORR and CR rates among high-risk subgroups, including refractory patients, were consistent with the overall study population. According to the public data, the biologic drug is currently under regulatory review in Europe and has received breakthrough therapy designation (BTD) in the US for the same indication.- Flcube.com
